Inhibrx Biosciences, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
| Przychód (średnia) |
0.10 |
2.00 |
2.16 |
116.93 |
208.78 |
| Przychód Δ r/r |
0.00% |
1895.00% |
8.30% |
5312.17% |
78.55% |
| Przychód (min) |
0.10 |
2.00 |
2.16 |
116.93 |
208.78 |
| Przychód (max) |
0.10 |
2.00 |
2.16 |
116.93 |
208.78 |
| EBITDA (średnia) |
-0.06 |
-1.20 |
-1.30 |
-70.16 |
-125.27 |
| EBIT (średnia) |
-0.06 |
-1.20 |
-1.30 |
-70.16 |
-125.27 |
| EBIT % |
-60.00% |
-60.00% |
-60.00% |
-60.00% |
-60.00% |
| Zysk netto (średni) |
1,615.44 |
-162.20 |
-133.76 |
-58.77 |
-16.50 |
| Zysk netto % |
1615438.62% |
-8130.45% |
-6191.04% |
-50.26% |
-7.90% |
| EPS (średnia) |
111.59 |
-11.21 |
-9.24 |
-4.06 |
-1.14 |
| Liczba analityków (Przychody) |
1 |
1 |
1 |
1 |
1 |
| Liczba analityków (EPS) |
1 |
1 |
1 |
1 |
1 |
| symbol |
INBX |
INBX |
INBX |
INBX |
INBX |